Global Opioid-Induced Constipation Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Global Opioid-Induced Constipation Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Opioid-Induced Constipation market size was valued at US$ 2734 million in 2024 and is forecast to a readjusted size of USD 3706 million by 2031 with a CAGR of 4.5% during review period.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

This report is a detailed and comprehensive analysis for global Opioid-Induced Constipation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Opioid-Induced Constipation market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Opioid-Induced Constipation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Opioid-Induced Constipation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031

Global Opioid-Induced Constipation market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Opioid-Induced Constipation

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Opioid-Induced Constipation market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Opioid-Induced Constipation market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Market segment by Application

Hospital

Pharmacy

Other

Major players covered

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Opioid-Induced Constipation product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Opioid-Induced Constipation, with price, sales quantity, revenue, and global market share of Opioid-Induced Constipation from 2020 to 2025.

Chapter 3, the Opioid-Induced Constipation competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Opioid-Induced Constipation breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Opioid-Induced Constipation market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Opioid-Induced Constipation.

Chapter 14 and 15, to describe Opioid-Induced Constipation sales channel, distributors, customers, research findings and conclusion.